Ten-year experience with cyclosporine as primary immunosuppression in recipients of renal allografts.
Cyclosporine has been used as primary immunosuppression in renal allograft recipients in our unit for the past decade. The overall clinical experience and long-term effects of the agent are reviewed. There were 461 consecutive recipients of kidney grafts; 379 received grafts from cadaver donors (CAD) and 82 from living related donors (LRD). Four separate clinical protocols were used sequentially using progressively decreasing doses of CyA; azathioprine was added in group 4 recipients of LRD grafts, and in patients receiving secondary CAD grafts (group 5). The patient mortality rate was less than 5%, with sepsis being the prime contributor. The majority of kidney grafts were lost within the first 2 months after operation; those that never functioned were found almost invariably to have been irreversibly rejected. During the subsequent years of follow-up, attrition of CAD grafts was significantly greater than LRD grafts. In contrast, the attrition rate of primary and secondary CAD grafts was the same after the first 3 months, emphasizing the importance of early immunologic graft destruction. Primary nonfunction occurred in 49% of CAD kidneys and 17% of LRD grafts; however 71% of initially nonfunctioning LRD grafts never functioned at all compared to 34% of CAD grafts, the majority of such organs undergoing fulminate rejection. Individual graft loss after 1 year was almost inevitably due to chronic rejection; there were no differences in long-term allograft function among the treatment groups. Although CyA has improved overall results of kidney transplantation, chronic rejection remains a major unresolved problem.
Tilney
N L
NL
Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts 02115.
Chang
A
A
Milford
E L
EL
Whitley
W D
WD
Lazarus
J M
JM
Ramos
E L
EL
Strom
T B
TB
Carpenter
C B
CB
Kirkman
R L
RL
D000328:Adult; D001379:Azathioprine / Q000008:administration & dosage / Q000627:therapeutic use; D001900:Boston / Q000453:epidemiology; D002423:Cause of Death; D002985:Clinical Protocols / Q000592:standards*; D003524:Cyclosporins / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000187:drug effects / Q000276:immunology*; D006085:Graft Survival / Q000187:drug effects / Q000276:immunology; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality; D008297:Male; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use; D015996:Survival Rate; D014181:Transplantation Immunology
D003524:Cyclosporins; D001379:Azathioprine; D011241:Prednisone